
SCHOOL OF MEDICINE IN SHREVEPORT

Louisiana State University Medical Center 1501 Kings Highway



Department of Psychiatry

December 14, 1999

Jamie Mullen Zeneca Pharmaceuticals FOC 2 SW 1800 Concord Pike PO Box 15437 Wilmington, DE 19850



Dear Mr. Mullen,

Dr. Anita Kablinger in our department passed your name on to me in the context of possibilities for obtaining sponsored research support in the area of psychiatric drugs. We are currently studying the regulation of glucose transport as it relates to diabetes and psychiatric disorders. Our group has discovered that certain antipsychotic medications block glucose transport into neuronal cells at physiologically relevant concentrations. These same drugs have also been associated with the induction of hyperglycemia and diabetes in patients. At the moment, we are trying to understand how these drugs block glucose transport and whether these effects on glucose uptake contribute to either the therapeutic benefits or to the side effects of these drugs. We are very interested in learning how your company's drug, quetiapine, behaves in this system. It will be especially important to determine if any of the newer atypical antipsychotic drug are distinguished by a lack of interference with glucose transport. Consequently, we have prepared a 2 page summary of a research project that we hope you will consider for possible funding. If there is interest in the project, a more complete proposal could be submitted and we would be happy to visit with your scientists if this would facilitate a decision on our funding request. Copies of several recent publications are enclosed for your information.

My phone number is 318 675-7612 and my email address is ddwyer@lsumc.edu if you would like to discuss this matter further.

Sincerely,

Donard S. Dwyer, Ph.D.

Associate Professor of Psychiatry and Pharmacology